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ABSTRACT 
Repaglinide is considered the drug of choice for diabetic patients with impaired kidney function as it is excreted mainly in the bile. Unfortunately, it 
possesses low oral bioavailability of approximately 56 %. Therefore, nano-sized globules containing the drug are expected to enhance its 
bioavailability and sustain its glucose lowering action. Self nano-emulsifying drug delivery systems (SNEDDS) of repaglinide have been prepared for 
improving the water solubility and oral bioavailability of the drug. Various compositions of SNEDDS were prepared using four types of oils (oleic 
acid, isopropyl myristate IPM. Labrafil 1944 and 2125), surfactants (chromophore El35, chromophore RH 40, Labrasol and Span 20) and a variety of 
co-surfacatnts. Low energy emulsification was adopted as the method of preparation for its feasibility and low cost. The prepared nano-emulsions 
showed small average droplet size (13.5-20 nm) and low polydispersity index (0.10 - 0.30). In-vitro dissolution studies indicated that the drug 
release from some of the prepared nanoemulsion droplets reached 75 % within the first 30 minutes. The in-vivo data demonstrated that repaglinide 
in the nano-emulsion formulations F8 (IPM, Cremophor EL35 and Propylene glycol) and F16 (Oleic acid, Cremophor RH40 and Lauroglycol FCC) 
lowered the plasma glucose level (< 110 mg/dL) of experimental rabbits in a similar trend to that of the commercial product (Novonorm
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), 
moreover, it caused an excess reduction in blood glucose level at the end of the 24 hrs period by virtue of its long circulation time compared to the 
marketed formula. 
 
INTRODUCTION 
Self-emulsifying drug delivery systems (SEDDS) are considered 
excellent alternatives to conventional dosage forms by virtue of their 
high solubilization and permeation attributes suited for poorly 
soluble and slowly absorbable drugs. SEDDS are isotropic mixtures 
of oils, surfactants/solvents and co-solvents/co-surfactants. They 
can be specially designed to improve the oral absorption of highly 
lipophilic drugs [1]. Depending on the method of preparation; either 
a self-microemulsifying drug delivery system (SMEDDS) or a self-
nanoemulsifyingdrug delivery system (SNEDDS) is obtained. Both 
systems have common characteristics to the extent that sometimes 
makes it difficult to differentiate between them. However, nano-
emulsions have some special advantages over micro-emulsionssuch 
as being transparent or translucent in color, having smaller droplet 
size (50-200 nm) andpossessinglong term physical-stability against 
sedimentation or creaming[2]. Identification of nano-emulsion 
formation can be done using ternary/pseudoternary phase 
diagrams[3]. Repaglinide is an oral blood glucose-lowering drug 
which belongs to themeglitinide class. It has been used in the 
treatment of type 2 diabetes. It exerts its action by stimulation of 
beta cells for insulin secretion in the pancreatic islets[4]. It has a 
short elimination half-life (1 hour) and a low oral bioavailability 
which reach about 56 % [5]. However, it is considered the drug of 
choice for diabetic patients with impaired kidney function as it is 
excreted mainly in the bile [6]. Therefore, combining the benefits of 
SNEDDS with those of repaglinide, a delivery system overcoming the 
drawbacks of the drug and capable of offering an effective 
andprolonged control of blood sugar levels will be developed. This 
study will focus on optimization, physicochemical characterization, 
in vitro and in vivo assessment of the developed formulation.  
MATERIALS AND METHODS 
Materials 
Repaglinide was a gift from The Egyptian International 
Pharmaceutical Industries Co. "EIPICO", Cairo, Egypt. Oleic acid, 
ispropylmyristate (IPM)and Span 20 (sorbitanmonolaurate) were 
purchased from Sigma Aldrich, USA. Labrafil 1944 (oleoyl polyoxyl-6 
glycerides) andLabrafil 2125 (linoleoyl polyoxyl-6 glycerides)were 
gifts fromGattefosse, Saint-Priest Cedex, France. Cromophor El 35 
(polyoxyl 35 castor oil), Cremophor RH 40 (polyoxyl 40 
hydrogenated castor oil), ethanol and Propylene glycol were 
purchased from El Gomhoria Pharm. Chem. Co., Egypt. 
Labrasol(caprylocaproyl polyoxyl-8 glycerides), Lauroglycol FCC 
(propylene glycol monolaurate) were gifts from Gattefosse, Saint-
Priest Cedex, France. The commercial product; Novonorm 0.5 mg 
tablets, NovoNordisc, Bagsvaerd Denmark, was purchased from the 
Egyptian Company for medicinal trades, Cairo, Egypt. 
Components screening 
The solubility of repaglinide in different nano-emulsion components 
including oils, surfactants and co-surfactants was evaluated by 
dissolving a known amount of repaglinide (10 mg) in 2 ml of each of 
oil, surfactant andcosurfactants using 5-mlcapacity vials. The vials 
were then sealed carefully with rubber stoppers and mixed using a 
vortex (Nickel- Electro Ltd, Oldmixon Crescent, UK). The vials were 
then placed in an isothermal shaker (Nirmal International. New 
Delhi, India) operated at 40 ºC till equilibrium. The mixtures were 
removed from the shaker and the contents transferred to 5 ml 
centrifuge tubes followed by centrifugation at 5000 rpm for 30 
minutes using refrigerated large capacity centrifuge(Union 32R, 
Korea). The supernatant was then separated, filtered using a 0.45-
μm membrane filter and its contentdetermined using UV-
Spectrophotometer (UV-240 1PC, Shimadzu, Japan) at 283.2 nm. 
Construction of pseudoternary phase diagrams 
Pseudoternary phase diagrams of oil, surfactant/cosurfactant 
mixture (S-mix.) and aqueous phase were constructed using the 
aqueous titration method [7]. The boundaries of phase diagrams 
designated the system's three components; one axis representing 
the aqueous phase, the second for the oil, and the third representing 
the S-mix[8]. Selected nano-emulsion components based on the 
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solubility study were incorporated in the final formulations using 
varieties of weight ratios. The surfactant/cosurfactant mixtures 
were prepared in ten weight ratios, then the oil was added to 
previous mixtures of surfactant/cosurfactantin the ratio of oil:S-mix; 
1:9, 2:8, 3:7, 4:6 and 5:5. The aqueous phase (distilled water) was 
added portion wise to the previous mixtures of oils and S-mix up to a 
final volume of 10 milliliters. The area of nanoemulsion formation 
was identified for the respective system in which transparent and 
easily flowable oil-in-water (o/w) nanoemulsions with desired 
globule size were obtained. 
Characterization of SNEDDS 
Morphology 
Samples of the nano-emulsion formulations were examined at high 
magnification using transmission electron microscopy (TEM)[9], 
(JEOL-JSM-6510LA Analytical Scanning Microscope, JEOL Ltd., 
Japan) to determine the particles morphology. 
Evaluation of particle size and zeta potential 
Evaluation of average particle size, size distribution and zeta 
potential of each sample was carried out using Malvern master sizer, 
Hydro 2000S, UK. 
In-vitro release studies 
The release of repaglinide from the prepared formulations was 
determined using USP Dissolution Apparatus 2 – Paddle type (37°C). 
In this method 1 ml of the preparednano-emulsion base (mixture of 
oil, surfactant and co-surfactant) containing 0.50 mg repaglinide 
were filled into hard shell capsules (size 1) then dropped in a 
dissolution medium of 1000 ml 0.1N HCL. Samples of 5 mls from the 
dissolution medium were withdrawn after specific time intervals 
(15, 30, 60, 90, 120,150 and 180 minutes) and replaced with fresh 
0.1N HCl. Samples were assessed spectrophotometrically. 
In-vivo studies 
Samples of the prepared nano-emulsion base (mixture of oil, 
surfactant and co-surfactant) containingrepaglinide were filled into 
hard shell capsules (size 1). The content of each capsule was 
determined based on animal dosing calculated according to Paget 
and Barnes calculations [10]. In this experiment 6 male albino 
rabbits weighing (2.5-3.0 kg) were selected for the test.  
The animals fasted overnight prior to oral dosing of the test samples. 
Randomized cross-over design was adopted for comparing the 
pharmacology of both SNEDDS formulations and the marketed 
product (Novonorm® 0.5). Samples of animal blood (one drop) 
were withdrawn at zero time and at time interverals (30 min and 
1,2,3,4,5,6,8,10,12,18,24 hrs) directly onto the strip of an automatic 
blood glucose checking apparatus (Accu-Chek Active blood glucose 
meter, ROCHE, Germany). The results were taken in triplicate for 
both the control and treatment groups (Fig. 4). 
RESULTS AND DISCUSSION 
Components screening 
The components of SNEDDS and their concentration have profound 
effects on the various characteristics of nanoemulsions, such as 
droplet size, polydispersity index, self-nanoemulsification time and 
in vitro drug release. Hence, it is important to optimize the quantities 
of the SNEDDS components after initial selection. The initial 
selection of the components can be on the basis of their ability to 
solubilize the drug of interest. Solubility of repaglinide in various 
SNEDDS components is presented in table 1.  
The results indicated that among the tested oils,repaglinideshowed a 
very high solubility in isopropyl myristate (IPM) where 180 µg/ml 
dissolved after 72 hours. The evaluated solubility of repaglinide in 
different surfactants demonstrated the superiority of Cremophor 
EL35 and Cremophor RH40 over others and hence they were 
employed in most formulations. Ethanol, Lauroglycol FCC and 
Labrasolwere selected as cosurfactants governed mainly by both 
their emulsification efficiency more than their ability to solubilize 
repaglinide. 
Table 1: Solubility of repaglinide in various nano-emulsion 
components 
Component Total Solubility (µg/mL) 
24 hrs 48 hrs 72 hrs 
Oleic acid 11.34 21.22 28.29 
Olyl alcohol 13.17 17.15 43.53 
IPM 147.07 163.65 180.73 
Labrafil 2125 ---- ---- 14.14 
Labrafil 1944 ---- ---- 15.85 
CremophorEL35 ---- ---- 161.34 
Cremophor RH40 ---- ---- 103.53 
Span 20 40.85 58.17 136.7 
 
Phase study 
Fourty systems were prepared with the oils, surfactant/cosurfactant 
(S/CoS) combinations listed in table 1. 
Each system was prepared with S/CoS weight ratios from 1:9 to 9:1. 
Pseudoternary phase diagrams were constructed using water 
titration method to identify transparent nanoemulsions at a 
temperature of 25±1ºC, which corresponds to common conditions of 
preparation, storage and application of pharmaceutical 
nanoemulsions. The nanoemulsion region appeared on the phase 
diagram as shaded areas (data not shown). The rest of the regions 
on the phase diagrams represent turbid and conventional emulsions 
based on visual observations. No liquid crystalline structures were 
observed under light microscope. Within the grey areas, the 
nanoemulsions were formed with only gentle vortexing. This is 
possible as surfactant strongly localized on the surface of the 
emulsion droplets reduces interfacial free energy and provides a 
mechanical barrier to coalescence resulting in a thermomechanically 
spontaneous dispersion.  
It was observed that the nanoemulsion existence areas obtained 
with more oils to S/CoS ratios were obtained for IPM compared to 
oleic acid and Labrafil®
11
 1944 and 2125. This finding is expected as 
the phase behaviour is strongly influenced by the size of the 
molecule of the oil used [ ]. Depending on the chain length and on 
the volume of the molecules, penetration of the surfactant into the 
hydrocarbon tails is expected to change the hydrocarbon chain 
volume of the surfactant molecule and thus, the effective critical 
packing parameter (CPP)[12], Since oleic acid and Labrafil®
The nano-emulsion droplets were evaluated for average diameter 
and zeta potential as shown in table 3. All nanoemulsion 
preparations were in the defined nanoemulsion droplet diameter 
(13.51 ± 0.08 - 19.68 ± 0.36 nm). The small average diameters of 
nanoemulsion droplets is mainly due tocosurfactant molecules 
penetrating the surfactant film, lowering the fluidity and surface 
viscosity of the interfacial film, decreasing the radius of curvature of 
the microdroplets and forming transparent nanosized systems [
1944 
and 2125 have large molecular size compared to that of IPM and to 
that of the surfactants used, low degree of oil penetration was 
expected to take place in the interfacial surfactant layer.  
A distinct central core, which greatly disrupts the packing of the 
surfactant molecules in this region, could be formed causing 
destabilization of the nanoemulsion with consequent reduction in its 
existence with different oil: S/CoS ratios. From the results obtained 
as well. It was also evident that CremophoreEL35/Labrasol and 
Cremophor RH40/Labrasol S-mix has larger nanoemulsification 
range as compared to other S-mix. Composition of selected self 
nanoemulsifying systems from all prepared formulations is 
presented in table 2. 
Droplet size and zeta potential 
13] 
The smallest average size (13.51 nm) was obtained from Formula S5 
composed of IPM/CremophoreEL35/Labrasol (10/20/70 % w/w). 
Formula S8 composed of IPM/Cremophore EL35/propylene 
glycol(10/90/0 % w/w) showed the highest average droplet 
size;19.68 nm. Since both formulations are prepared using the same 
oil and surfactant, the difference in particle size might be mainly 
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attributed to the cosurfactant effect; no clear mechanism was found 
to elucidate this influence. PDI was less than 0.35 and zeta potential 
values were sufficient for maintaining stable nanoemulsion 
preparations.  
Stabilizers presented as surfactants and cosurfactants are meant to 
wet the surfaces of the particles and retard Ostwald ripening and 
agglomeration to increase the stability of the preparation by 
providing a steric barrier. 
 
Table 2: Composition of selected nanoemulsionformualtions 
Formula Repaglinide 
(mg) 
Oil (0.1-0.9 
mL) 
S-mix (0.9-0.1 mL) S-mix 
ratio 
Oil: S-mix 
ratio 
Aqueous phase 
(mL) Surfactant (mL) Cosurfactant 
(mL) 
S5 0.50 IPM Cremophor El-35 Labrasol 1/9 
2/8 
3/7 
4/6 
0.1/0.9 Water to 10 mL 
 
S8 0.50 IPM Cremophor El-35 Propylene glycol 10/0 0.1/0.9 
S9 0.50 IPM Labrasol Ethanol 8/2 
9/1 
0.1/0.9 
S10 0.50 IPM Cremophor RH-
40 
Labrasol 1/9 
2/8 
3/7 
4/6 
5/5 
0.1/0.9 
    5/5 
6/4 
0.2/0.8 
S16 0.50 Oleic acid Cremophor RH-
40 
Lauroglycol FCC 9/1 10/0 0.1/0.9 
S39 0.50 Labrafil 1944 Cremophor El-35 Ethanol 7/3 0.2/0.8 
S40 0.50 Labrafil 2125 Cremophor El-35 Ethanol 8/2 0.1/0.9 
 
Characterization 
Morphology 
Transmission electron microscopy (TEM) was utilized for 
elucidating morphology of the prepared nanoemulsions. 
Photographs of TEM (Figs. 1-3) demonstrate clearly the spherical 
outlines of nanoemulsion droplets. 
 
 
Fig. 1: Scanning electron micrographs of nano-emulsion 
globules (Formulation S8) 
 
In-vitro release studies 
The in vitro drug release study represents a very important 
parameter in the prediction of drug bioavailability form different 
formulations. Comparing the release profile of repaglinide from the 
selectednano-emulsion formulations to that of Novonorm®
Randomized cross-over design was adopted for comparing the 
pharmacology of both SNEDDS formulations and the marketed 
product (Novonorm® 0.5). The anti-diabetic activity of the 
promising nanoformulations S8 (IPM/CremophoreEL35/Labrasol) 
and S16 (Oleic acid/Cremophore RH40/Lauroglycol FCC) vs a 
control as well as a repaglinide market product showed that both 
repaglinide SNEDDS formulations showed percentage reduction in 
blood glucose level comparable to the reference drug with S16 
showing lower glucose levels at certain points during and till the end 
of the 24 hrs. period (Fig. 4). 
 
 tablets 
(0.5 mg), Formula S8 composed of IPM/Cremophore EL35/ 
propylene glycol (10/90/0 % w/w) was found promising where it 
showed a biphasic zero order release profile with a rapid initial 
burst that lasted for about 30 min at which approximately 93% of 
the drug content was released from the SNEDDS this was followed 
by a slower and more gradual drug release pattern reaching approx-
imately 100% at 3 h (table 4), a comparable release pattern was 
achieved with S16 as well. 
In-vivo studies 
 
Fig. 2: Scanning electron micrographs of nano-emulsion 
globules (Formulation S40) 
 
 
Fig. 3: Scanningelectron micrographs of nano-emulsionglobules 
(Formulation S16)
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Table 3: Average size, size distribution and zeta-potential of prepared repaglinidenano-emulsions 
Formula Specific surface 
area (m2
Average P. size 
(nm S. D) /g) 
Mean diameter (nm) Average polydispersity 
index S. D 
Average Zeta pot. 
(mV) ± S. D D (10 
%) 
D (50 
%) 
D (90 
%) 
S5 66.40 13.51 ± 0.08 64 94 138 0.165 ± 0.02 -8.68 ± 2.16 
S8 32.90 19.68 ± 0.36 157 182 220 0.317 ± 0.03 -3.80 ± 0.18 
S9 35.40 21.04 ± 0.08 128 173 240 0.167 ± 0.01 -28.7 ± 0.92 
S10 22.42 23.46 ± 0.91 1697 2564 4323 0.230 ± 0.01 -29.35 ± 1.67 
S16 21.50 15.62 ± 0.02 173 228 3447 0.119 ± 0.02 -3.20 ± 0.01 
S40 22.40 18.65 ± 0.04 174 267 584 0.214 ± 0.01 -3.52 ± 0.56 
 
Table 4: Percentage repaglinide released from prepared nano-emulsion formulations and the marketed product 
Formulation pH % released after Q (hours)  
Q Q½hr Q1½hr 3hr 
S5 4.76 12.20 85.51 101.64  
S8 4.01 93.52 108.78 102.39  
S16 4.58 88.49 104.01 95.51  
S40 3.86 24.32 73.38 99.19  
Novonorm® 0.5 --- 52.91 61.64 111.54  
 
 
Fig. 4: In-vivostudy 
 
CONCLUSION 
SNEDDS of repaglinide showed satisfactory physicomechanical 
characteristics. The selected formulations S8 and S16 of 
repaglinideSNEDDS gave a reasonable invitrorelease profile 
compared to the market product. Combining the benefits of SNEDDS 
with the effectiveness of repaglinide, a promising antidiabetic drug 
delivery system could be achieved. 
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